Kinapse and BioClinica Partner to Accelerate

Posted by Kinapse on 21 May 2015

NEWTOWN, PENNSYLVANIA, May 21, 2015 – BioClinica®, Inc., a leading specialty clinical trials services and technology provider, today announced it has partnered with Kinapse to accelerate Risk-Based Monitoring (RBM) implementation on global clinical trials using BioClinica’s Compass Intelligent Monitoring solution.

“Implementing a comprehensive RBM solution can make a real difference in clinical research,” BioClinica CEO John Hubbard said. “We’re excited about this collaboration as it helps move the industry forward with intelligent monitoring by bringing together our technology and subject matter expertise with Kinapse’s broad implementation experience.”  

Kinapse employs 450 professionals globally and has more than ten years of experience providing strategy and operations consultancy and capability-building programs, including RBM, to life sciences companies.

“In evaluating RBM-enabling technologies, we found BioClinica’s Compass provides one of the most comprehensive solutions,” said Stuart Donald, vice president of advisory services of Kinapse. “Compass is uniquely designed for RBM and has a rich tool set to solve risk and quality issues, making it the right technology in this new era of monitoring.”

Kinapse’s role includes easing the change management process as organizations transition to RBM. “We manage implementation from start to finish, including development of supporting processes,” Donald said.

The partnership comes at a time of increasing demand for Compass and as several pilot studies using the technology show significant improvement in quality and risk reduction. BioClinica’s Vice President of Clinical Innovation, Courtney McBean explained, “Compass catches issues that often go overlooked by onsite monitoring until later in the trial. Finding and fixing issues sooner is less costly and less risky than dealing with bigger problems down the road, especially when it comes to quality and safety.”    

BioClinica and Kinapse will make a joint presentation, Essential Steps to Successful Risk-Based Monitoring, on June 4 in Tokyo, Japan.

To learn more about BioClinica’s Compass, contact Courtney McBean by emailing Courtney.McBean@BioClinica.com or calling (952) 905-8810. Follow BioClinica on the Trial Blazers blog at http://www.bioclinica.com/blog, and on Twitter at http://twitter.com/bioclinica.

About BioClinica, Inc.

BioClinica is a specialty clinical trials services provider that improves the development of new medical therapies by delivering expertise and technologies that enhance clinical research data and analytics, worldwide. The company offers industry-leading medical imaging services, enterprise eClinical technologies, clinical research centers and cardiovascular safety solutions that bring quality and efficiency to every phase of clinical development. BioClinica’s experience spans three decades and includes thousands of studies in all therapeutic areas. The company serves more than 400 pharmaceutical, biotechnology, and device organizations – including all of the top 20 – through a network of offices in the U.S., Europe and Asia. For more information, please visit www.bioclinica.com.

Advise · Build · Operate